Celularity Inc.
CELUHealthcare|Biotechnology|US
$0.76
+0.03 (+4.80%)
Cash / Share
$0.02
Clinical Trials (17)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT01261403 Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Active Rheumatoid Arthritis | Rheumatoid Arthritis | P2 | Terminated | 26 | RCT, Double-blind | PDA001, Vehicle Controlled Placebo |
| NCT02552277 A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy | Diabetic Nephropathies, Peripheral Nervous System Diseases | P2 | Completed | 26 | RCT, Double-blind | PDA-002, Placebo |
| NCT04365101 Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 | Coronavirus, Coronavirus Infection | P1P2 | Terminated | 7 | RCT, Open-label | CYNK-001 |
| NCT01155362 PDA001 for the Treatment of Adults With Moderate-to-Severe Crohn's Disease | Crohn's Disease | P2 | Completed | 50 | RCT, Double-blind | Human Placenta-Derived Cells PDA001 Intravenous Infusion, Vehicle Control |
| NCT02264288 Efficacy and Safety of Intramuscular PDA-002 in Subjects With Diabetic Foot Ulcer With and Without PAD. | Peripheral Arterial Disease, Diabetic Foot | P2 | Terminated | 159 | RCT, Double-blind | PDA-002 |
| NCT05218408 CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type | Astrocytoma, Grade IV, Glioblastoma | P1P2 | Withdrawn | — | Open-label | CYNK-001 systemic and Intra cavity administration |
| NCT02460081 Hemodynamic Effects of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With Peripheral Arterial Disease | Diabetic Foot, Peripheral Arterial Disease | P2 | Withdrawn | — | RCT, Double-blind | PDA-002, Placebo |
| NCT01310114 Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Ischemic Stroke | Stroke, Acute, Middle Cerebral Artery Stroke | P2 | Terminated | 44 | RCT, Double-blind | Human Placenta-Derived Cells PDA001- (cenplacel-L), Placebo |
| NCT05207722 CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma | Metastatic HER2 Positive Gastroesophageal Junction Cancer | P1P2 | Terminated | 1 | Open-label | CYNK-101, Pembrolizumab, Trastuzumab, Recombinant Human Interleukin-2, Cyclophosphamide, Fludarabine, Mesna |
| NCT04489420 Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM | Astrocytoma, Grade IV, Giant Cell Glioblastoma | P1 | Terminated | 3 | Open-label | CYNK001-IV, CYNK001-IT |
| NCT02781467 A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML) | Leukemia, Myeloid, Acute | P1 | Terminated | 10 | Open-label | PNK-007, Cyclophosphamide, Fludarabine, Human recombinant Interleukin-2 (rhIL-2) |
| NCT01769755 A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease | Crohns Disease | P1 | Completed | 14 | RCT, Double-blind | PDA001, Vehicle Controlled Placebo |
| NCT02955550 A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM) | Multiple Myeloma | P1 | Completed | 15 | Open-label | rhIL-2, PNK-007 |
| NCT04309084 Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma | Multiple Myeloma, Neoplasm, Plasma Cell | P1 | Unknown | 29 | Open-label | CYNK-001 |
| NCT04310592 Natural Killer Cell (CYNK-001) Infusions in Adults with AML | Leukemia, Leukemia, Myeloid | P1 | Terminated | 27 | Open-label | CYNK-001 |
| NCT01440192 Safety of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Stage II or III Pulmonary Sarcoidosis | Stage 2 Pulmonary Sarcoidosis, Stage 3 Pulmonary Sarcoidosis | P1 | Terminated | 4 | Open-label | PDA001 (cenplacel-L) |
| NCT01859117 Study of PDA-002 in Subjects With Peripheral Arterial Disease and Diabetic Foot Ulcers | Peripheral Arterial Disease, Diabetic Foot Ulcer | P1 | Completed | 15 | Open-label | PDA-002 |